A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering

Journal of Cardiovascular Risk

Volumn 6, Issue 5, 1999, Pages 337-346

  Ginsberg, Henry ^a,d   Plutzky, Jorge ^b   Sobel, Burton E ^c  

^a Columbia University ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Antidiabetic agents; Cardiovascular disease; Diabetes; Endothelial function; Fibrinolysis; Lipids; Metformin; Sulfonylurea; Thiazoladinediones; Thrombosis

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; INSULIN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

BLOOD CLOT LYSIS; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; LIPID OXIDATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; BLOOD VESSEL WALL; COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFECT; GLYCEMIC CONTROL; HYPERINSULINEMIA; HYPERPLASIA; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SMOOTH MUSCLE;

EID: 84910011021     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1177/204748739900600512     Document Type: Review

References (97)

1. Reaven GM. Syndrome X: 6 Years later. J Intern Med 1994; 236 (suppl 736):13-22.
2. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105 (suppl 1A):4S-14S.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
4. Deedwania PC. The deadly quartet revisited. Am J Med 1998; 105 (suppl 1A):1S-3S.
5. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Harris MI (editor): Diabetes in America. Second Edition. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 1995. pp. 233-257.
6. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998; 21:1138-1145.
7. DeFronzo RA. The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 1988; 37:667-687.
8. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widén E, Schalin C, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321:337-343.
9. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990; 113:909-915.
10. Henry RR. Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998; 105 (suppl 1A):20S-26S.
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
12. Reusch JE-B. Focus on insulin resistance in type 2 diabetes: Therapeutic implications. Diabetes Educ 1993; 24:188-193.
13. Edelman SV. Type II diabetes mellitus. Adv Intern Med 1998; 43:449-500.
14. Chiasson J-L, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19:1190-1193.
15. Noda K, Umeda F, Nawata H. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1997; 37:129-136.
16. Chiasson J-L, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Diabetes Care 1998; 21:1720-1725.
17. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26:553-573.
18. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872.
19. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM, Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:193-203.
20. Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes (NIDDM) [abstract]. Diabetes 1997; 46 (suppl 1):149A.
21. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46:433-439.
22. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188-1193.
23. Watanabe Y, Sunayama S, Shimada K, Sawano M, Mokuno H, Daida H, et al. Troglitazone improves endothelial function in patients with insulin resistance [abstract]. Circulation 1998; 98 (suppl 1):1111.
24. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.
25. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. Diabetes Care 1996; 19:64-66.
26. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19:64-66.
27. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229:181-187.
28. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46:454-457.
29. Brown V. Detection and management of lipid disorders in diabetes. Diabetes Care 1996; 19 (suppl 1):S96-S102.
30. Best JD, Jerums G, Newnham HH, O'Brien RC. Diabetic dyslipidaemia: Australian Diabetes Society position statement. Med J Aust 1995; 162:91-93.
31. Antonucci T, McLain R, Whitcomb R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20:188-193.
32. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquett TR, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12:181-186.
33. Tack CJJ, Demacker PNM, Smits P, Stalenhoef AFH. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21:796-799.
34. Nilsson-Ehle P, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 1980; 49:667-693.
35. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: A study of two ethnic groups. Diabetes Care 1993; 16:621-629.
36. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21:701-705.
37. Chan JCN, Cockram CS, Tomlinson B, Walden RJ, Critchley JAJH. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16:1035-1038.
38. Carlsen SM, Rossvoll O, Bjerve KS, Følling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996; 239:227-233.
39. Pentikäinen PJ, Voutilainen E, Aro A, Uusitupa M, Penttilä I, Vapaatalo H. Cholesterol lowering effect of metformin in combined hyperlipidemia: Placebo controlled double blind trial. Ann Med 1990; 22:307-312.
40. Snorgaard O, Køber L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242:407-412.
41. Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P, Rossi G, et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81:1568-1574.
42. Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Tohoku J Exp Med 1997; 183:173-183.
43. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: The epidemiologic evidence and beyond. Am J Epidemiol 1989; 129:249-259.
44. Cominacini L, Garbin U, Pastorino AM, Fratta Pasini A, Campagnola M, De Santis A, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994; 26:173-184.
45. Chait A, Brazg RL, Tribble DL, Kruass RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350-356.
46. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
47. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
48. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, et al. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 1997; 40:165-172.
49. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996; 123:227-234.
50. Cominacini L, Young MMR, Capriata A, Garbin U, Fratta Pasini A, Campagnola M, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia 1997; 40:1211-1218.
51. Cominacini L, Garbin U, Fratta Pasini A, Campagnola M, Davoli A, Foot E, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998; 47:130-133.
52. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997; 235:113-116.
53. Nagano Y, Nakamura T, Matsuzawa Y, Cho M, Ueda Y, Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit-long-term antiatherogenic effect and effects on established plaques. Atherosclerosis 1992; 92:131-140.
54. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43:920-928.
55. Rosenstock J, Raskin P. Hypertension in diabetes mellitus. Cardiol Clin 1988; 6:547-560.
56. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11:821-827.
57. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes 1998; 47:1643-1649.
58. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
59. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320.
60. Tack CJJ, Ong MKE, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: Effects of troglitazone. Diabetologia 1998; 41:569-576.
61. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47:810-814.
62. Driscoll J, Ghazzi M, Perez J, Huang S, Whitcomb R. A 96-week follow-up on cardiac safety in patients with type II diabetes treated with troglitazone [abstract]. Diabetes 1997; 46 (suppl 1):149a.
63. Murakami T, Mizuno S, Ohnaka M. Troglitazone restores endothelium-dependent vasomotion of resistance coronary artery [abstract]. Circulation 1998; 98 (suppl 1):1111.
64. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect. J Clin Invest 1995; 96:354-360.
65. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 1995; 44:1105-1109.
66. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994; 24:170-175.
67. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993; 265:R726-R732.
68. Peuler JD, Miller JA, Bourghli M, Zammam HY, Soltis EE, Sowers JR. Disparate effects of antidiabetic drugs on arterial contraction. Metabolism 1997; 47:1199-1205.
69. Schwartz S, Raskin P, Fonseca V, Graveline JF, for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338:861-866.
70. Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
71. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients-relationship with plasma insulin. Thromb Haemostas 1989; 61:370-373.
72. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42:945-949.
73. 2 synthesis in patients with diabetes mellitus. Chin Med J (Engl) 1990; 103:312-318.
74. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular disease? Diabetes 1983; 32 (suppl 2):14-19.
75. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97:87-96.
76. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfeld RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116.
77. Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47:1494-1500.
78. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202.
79. Grant PJ, Stickland MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med 1991; 8:361-365.
80. Ishizuka T, Taniguchi O, Yamamoto M, Kajita K, Nagashima T, Takeda N, et al. Thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulphonylurea or insulin. Diabetologia 1994; 37:632-638.
81. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
82. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960-967.
83. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). United Kingdom Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
84. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
85. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). Am J Med 1997; 102:38-47.
86. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17:1859-1867.
87. Marx N, Bourcier T, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression.: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19:546-551.
88. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83:1097-1103.
89. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:17-23.
90. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95:7614-7619.
91. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
92. Spiegelman BM. PPARγ in monocytes: Less pain, any gain? Cell 1998; 93:153-155.
93. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98:1897-1905.
94. Morkang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997; 10:440-446.
95. Spencer CM, Markham A. Troglitazone. Drugs 1997; 54:89-101.
96. Peuler JD, Phare SM, Iannucci AR, Hodorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996; 9:188-192.
97. Delaey C, Van de Voorde J. Heterogeneity of the inhibitory influence of sulfonylureas on prostanoid-induced smooth muscle contraction. Eur J Pharmacol 1997; 325:41-46.